CABP5

Across TCGA pan-cancer cohorts, CABP5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CABP5 data layer compared with 14 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CABP5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CABP5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where CABP5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.665	1.000	.001	34	view →
PDAC	OS	Median	III,IV	0.885	0.603	.014	7	view →
LUAD	DFS	Median	III,IV	0.818	0.194	.026	3	view →
GBM	OS	Median	All	0.725	0.430	.020	2	view →
UCEC	DFS	Median	All	1.000	0.823	.017	2	view →
CCRCC	DFS	Median	All	0.684	0.978	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CABP5–LSCC (OS)

Open the LSCC breakdown →